COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES

This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequenti...

Full description

Saved in:
Bibliographic Details
Main Authors BEEBE, JEAN, SACCUZZO, JANI, JITESH, PRANLAL, HEALEY, DIANE, INGEBORG, O'LEARY, JAMES, JOHN, SCHAEFFER, TRACEY, LEE, FERRANTE, KAREN, JEAN
Format Patent
LanguageEnglish
French
German
Published 29.06.2005
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan, and Camptosar(R), an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypertensive agent.
Bibliography:Application Number: EP20030792573